First effects of meningococcal C vaccination campaign in the Netherlands

Greeff, Sabine de; Ruijs, Helma; Timen, Aura; Deuren, Marcel van; Melker, H de; Spanjaard, Lodewijk; Dankert, J.; Vries, Marion de

doi:10.2807/esw.07.30.02264-en

Cited by 5 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Incidence of meninogococcal C disease decreased soon after the vaccination campaign was carried out. 47,48 The number of patients with meningococcal C disease in the first three months after the campaign (November 2002-January 2003) decreased from 97 to 11 (89%) compared with the same period of the previous year.…”

Section: Human Vaccines 135mentioning

confidence: 99%

“…2,57,58 GCMP-TT was used for the catch-up campaign of children 1 to 18 years of age in the Netherlands in 2002, and the incidence of meningococcal C infections were reduced by almost 90%. 47,48 Meningococcal C conjugate vaccines are clearly superior to the available polysaccharide vaccines in protecting infants and stimulating long-term immunity for all ages. In addition, unlike polysaccharide vaccines, the conjugate meningococcal C vaccines appear able to reduce the carriage of meningococci 59 and contribute to the control of meningococcal infection by indirect protection through herd immunity.…”

Section: Human Vaccines 137mentioning

confidence: 99%

See 1 more Smart Citation

Group C Meningococcal Polysaccharide-Tetanus Toxoid Conjugate Vaccine: A Meta-Analysis of Immunogenicity, Safety and Posology

Pöllabauer¹,

Petermann²,

Ehrlich³

2005

Human Vaccines

View full text Add to dashboard Cite

A conjugate vaccine comprised of de-O-acetylated group C meningococcal polysaccharide coupled to tetanus toxoid (GCMP-TT) has been licensed in 32 countries and incorporated in a comprehensive UK vaccination program. Extensive evidence, forming the subject of this meta-analysis, has rapidly accumulated on the immunogenicity, safety and posology of GCMP-TT as well as its epidemiological impact. GCMP-TT has been shown effective after a single dose in individuals >12 months of age, and initial posology specified three doses in infants. However, based on a recent clinical trial, posology was reduced to two doses in infants. Pooled protection rate, defined as proportion of subjects with serum bactericidal antibody (SBA) levels > or = 1:8, was 99.4% (CI, 98.2-99.9%) in seven clinical trials covering all age groups. Robust responses to GCMP-TT have been demonstrated with respect to SBA, IgG levels and antibody avidity. In post-marketing pharmacosurveillance encompassing >12 x 10(6) GCMP-TT doses distributed worldwide, the vaccine has been well tolerated with an incidence rate of 0.01% for all the most commonly encountered types of adverse events. After a catch-up UK vaccination campaign where 5-8 year old children were primarily given GCMP-TT, a 93% decline in meningococcal disease incidence was observed. In view of its immunogenicity, safety and potential suitability for use among infants in reduced dose schedules, GCMP-TT appears to mark a major advance over predecessor polysaccharide vaccines for the prevention of meningococcal C disease.

show abstract

Section: Human Vaccines 135mentioning

confidence: 99%

Section: Human Vaccines 137mentioning

confidence: 99%

Group C Meningococcal Polysaccharide-Tetanus Toxoid Conjugate Vaccine: A Meta-Analysis of Immunogenicity, Safety and Posology

Pöllabauer¹,

Petermann²,

Ehrlich³

2005

Human Vaccines

View full text Add to dashboard Cite

show abstract

“…By crossing these data with the vaccination records, this detailed study allowed us to fit an accurate waning seroprotection table for conjugate meningococcal C vaccination. This study is not only important for public health decisions in the immediate future in Spain [ 15 ] but also for other countries which have shifted from polysaccharide to conjugate vaccination in the last decade [ 16 - 18 ]. Nowadays, the situation referred to seroprotection in the Autonomous Community of Valencia can be considered very good, as reflected by the rareness of cases of meningococcal C disease.…”

Section: Discussionmentioning

confidence: 99%

Optimizing strategies for meningococcal C disease vaccination in Valencia (Spain)

et al. 2014

View full text Add to dashboard Cite

BackgroundMeningococcal C (MenC) conjugate vaccines have controlled invasive diseases associated with this serogroup in countries where they are included in National Immunization Programs and also in an extensive catch-up program involving subjects up to 20 years of age. Catch-up was important, not only because it prevented disease in adolescents and young adults at risk, but also because it decreased transmission of the bacteria, since it was in this age group where the organism was circulating. Our objective is to develop a new vaccination schedule to achieve maximum seroprotection in these groups.MethodsA recent study has provided detailed age-structured information on the seroprotection levels against MenC in Valencia (Spain), where vaccination is routinely scheduled at 2 months and 6 months, with a booster dose at 18 months of age. A complementary catch-up campaign was also carried out in n for children from 12 months to 19 years of age. Statistical analyses of these data have provided an accurate picture on the evolution of seroprotection in the last few years.ResultsAn agent-based model has been developed to study the future evolution of the seroprotection histogram. We have shown that the optimum strategy for achieving high protection levels in all infants, toddlers and adolescents is a change to a 2 months, 12 months and 12 years of age vaccination pattern. If the new schedule were implemented in January 2014, high-risk subjects between 15-19 years of age would have very low seroprotection for the next 6 years, thereby threatening the program.ConclusionsHigh protection levels and a low incidence of meningococcal C disease can be achieved in the future by means of a cost-free change in vaccination program. However, we recommend a new catch-up program simultaneous to the change in regular vaccination program.

show abstract

“…This success stimulated the introduction of MCC vaccines in a number of other countries and provides the prospect of serogroup C meningococcal disease control [78–80]. A number of studies conducted since the introduction of the vaccines have resulted in changes to the UK vaccination schedule, principally in light of the realization that carriage effects were more important than induction of immunological memory in individuals [81].…”

Section: The Development and Introduction Of Meningococcal Serogroup mentioning

confidence: 99%

The impact of protein-conjugate polysaccharide vaccines: an endgame for meningitis?

Maiden

2013

Phil. Trans. R. Soc. B

View full text Add to dashboard Cite

The development and implementation of conjugate polysaccharide vaccines against invasive bacterial diseases, specifically those caused by the encapsulated bacteria Neisseria meningitidis, Haemophilus influenzae and Streptococcus pneumoniae, has been one of the most effective public health innovations of the last 25 years. These vaccines have resulted in significant reductions in childhood morbidity and mortality worldwide, with their effectiveness due in large part to their ability to induce long-lasting immunity in a range of age groups. At the population level this immunity reduces carriage and interrupts transmission resulting in herd immunity; however, these beneficial effects can be counterbalanced by the selection pressures that immunity against carriage can impose, potentially promoting the emergence and spread of virulent vaccine escape variants. Studies following the implementation of meningococcal serogroup C vaccines improved our understanding of these effects in relation to the biology of accidental pathogens such as the meningococcus. This understanding has enabled the refinement of the implementation of conjugate polysaccharide vaccines against meningitis-associated bacteria, and will be crucial in maintaining and improving vaccine control of these infections. To date there is little evidence for the spread of virulent vaccine escape variants of the meningococcus and H. influenzae, although this has been reported in pneumococci.

show abstract

First effects of meningococcal C vaccination campaign in the Netherlands

Abstract: In response to the increasing incidence of meningococcal C disease in the Netherlands since 2000

Cited by 5 publications

References 0 publications

Group C Meningococcal Polysaccharide-Tetanus Toxoid Conjugate Vaccine: A Meta-Analysis of Immunogenicity, Safety and Posology

Group C Meningococcal Polysaccharide-Tetanus Toxoid Conjugate Vaccine: A Meta-Analysis of Immunogenicity, Safety and Posology

Optimizing strategies for meningococcal C disease vaccination in Valencia (Spain)

The impact of protein-conjugate polysaccharide vaccines: an endgame for meningitis?

Contact Info

Product

Resources

About